Profile data is unavailable for this security.
About the company
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
- Revenue in USD (TTM)398.20m
- Net income in USD71.41m
- Incorporated2006
- Employees167.00
- LocationCatalyst Pharmaceuticals Inc355 ALHAMBRA CIRCLE, SUITE 801CORAL GABLES 33134United StatesUSA
- Phone+1 (305) 529-2522
- Fax+1 (302) 636-5454
- Websitehttps://catalystpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | CPRX:NAQ since announced | Transaction value |
|---|---|---|
| Santhera Pharmaceuticals Holding-Vamorolone Drug | 23.36% | 231.00m |
Data delayed at least 15 minutes, as of Apr 30 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc | 582.02m | 128.85m | 1.66bn | 246.00 | 13.72 | 3.56 | 10.84 | 2.85 | 2.13 | 2.13 | 9.64 | 8.23 | 0.7837 | 25.10 | 9.03 | 2,365,943.00 | 17.35 | 7.46 | 20.74 | 9.08 | 79.17 | 80.58 | 22.14 | 10.46 | 2.72 | 21.27 | 0.293 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Supernus Pharmaceuticals Inc | 607.52m | 1.32m | 1.67bn | 652.00 | 1,207.10 | 1.82 | 19.43 | 2.76 | -0.0152 | -0.0152 | 10.71 | 16.84 | 0.4077 | 0.9918 | 3.92 | 931,780.70 | 0.0883 | 4.95 | 0.1315 | 6.41 | 86.21 | 88.61 | 0.2166 | 12.84 | 1.43 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 27.96m | -160.28m | 1.73bn | 154.00 | -- | 18.41 | -- | 61.77 | -2.04 | -2.04 | 0.3491 | 0.9768 | 0.188 | -- | 4.52 | 181,577.90 | -107.75 | -40.21 | -156.49 | -47.99 | 96.97 | -- | -573.17 | -374.75 | 3.36 | -13.94 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Inhibrx Inc | 1.80m | -241.36m | 1.79bn | 166.00 | -- | 37.20 | -- | 992.12 | -5.03 | -5.03 | 0.0382 | 0.9184 | 0.006 | -- | 3.53 | 10,843.37 | -80.07 | -77.06 | -93.12 | -93.91 | -- | -- | -13,318.17 | -1,590.91 | -- | -11.00 | 0.8263 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Myriad Genetics, Inc. | 753.20m | -263.30m | 1.79bn | 2.70k | -- | 2.27 | -- | 2.38 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Catalyst Pharmaceuticals Inc | 398.20m | 71.41m | 1.80bn | 167.00 | 25.00 | 4.21 | 17.23 | 4.51 | 0.6092 | 0.6092 | 3.56 | 3.62 | 0.9417 | 4.63 | 12.45 | 2,384,455.00 | 16.89 | 25.42 | 20.06 | 29.81 | 86.95 | 85.63 | 17.93 | 30.87 | 2.68 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.81bn | 112.00 | -- | 3.26 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Beam Therapeutics Inc | 377.71m | -132.53m | 1.81bn | 436.00 | -- | 1.83 | -- | 4.81 | -1.87 | -1.87 | 4.90 | 12.02 | 0.2697 | -- | -- | 866,305.10 | -9.46 | -24.54 | -11.17 | -29.26 | -- | -- | -35.09 | -211.96 | -- | -- | 0.0005 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Fusion Pharmaceuticals Inc | 2.07m | -94.90m | 1.82bn | 113.00 | -- | 7.67 | -- | 878.20 | -1.47 | -1.47 | 0.0315 | 2.79 | 0.0082 | -- | 60.82 | 18,300.88 | -37.59 | -35.45 | -40.07 | -38.55 | -- | -- | -4,588.83 | -7,206.24 | -- | -- | 0.1352 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.82bn | 93.00 | -- | 4.00 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Amneal Pharmaceuticals Inc | 2.39bn | -83.99m | 1.83bn | 7.70k | -- | 137.74 | 10.14 | 0.7657 | -0.3116 | -0.3116 | 13.46 | 0.0431 | 0.6583 | 2.83 | 3.53 | 310,858.10 | -1.34 | -4.80 | -1.70 | -5.93 | 34.28 | 34.76 | -2.04 | -9.00 | 0.9408 | 1.14 | 0.9778 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Agios Pharmaceuticals Inc | 26.82m | -352.09m | 1.84bn | 383.00 | -- | 2.26 | -- | 68.63 | -6.33 | -6.33 | 0.482 | 14.50 | 0.0247 | 0.209 | 10.69 | 70,033.95 | -32.36 | -29.54 | -34.43 | -31.88 | 89.26 | -- | -1,312.64 | -3,826.10 | 11.99 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Twist Bioscience Corp | 262.36m | -205.80m | 1.85bn | 919.00 | -- | 3.14 | -- | 7.06 | -3.60 | -3.60 | 4.59 | 10.21 | 0.3194 | 4.47 | 7.04 | 285,488.60 | -25.06 | -30.50 | -27.56 | -33.84 | 35.79 | 36.02 | -78.44 | -113.33 | 5.51 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
Data as of Apr 30 2024. Currency figures normalised to Catalyst Pharmaceuticals Inc's reporting currency: US Dollar USD
34.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 14.50m | 12.30% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 6.85m | 5.81% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.79m | 5.76% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 2.60m | 2.21% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.20m | 1.87% |
| Royce & Associates LPas of 31 Dec 2023 | 1.74m | 1.48% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.60m | 1.36% |
| Boston Partners Global Investors, Inc.as of 31 Dec 2023 | 1.54m | 1.31% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.48m | 1.26% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 1.40m | 1.19% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
